LEO Pharma's new drug study pulled before any volunteers enrolled
NCT ID NCT03995550
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was an early-stage study designed to check the safety and tolerability of a new drug called LEO 142397 in healthy people. The study was planned in two parts: one group would get a single dose, and another would take it daily for two weeks. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Covance Clinical Research Unit Ltd.
Leeds, LS2 9LH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test